ITCI
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. insider trading
Intra-Cellular Therapies, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Bedminster, NJ. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent ITCI insider transactions
Intra-Cellular Therapies, Inc.'s insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at ITCI spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
ITCI insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded ITCI on the open market: 0 purchases and 26 sales worth $35M, 25 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: no open-market trades at all.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | −$12.4M9 sales · all on a plan | |
| Q3 2024 | — | −$22.6M17 sales · 16 on a plan |
- Largest sale
- −$4.2M of ITCI by Mates Sharon (Chairman and CEO · Director) on Dec 05, 2024, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Mates Sharon10b5-1
Chairman and CEO · Director
−$4.2M
Dec 05, 2024
50,163 sh · $84.06
Mates Sharon10b5-1
Chairman and CEO · Director
−$129.9K
Dec 05, 2024
1,534 sh · $84.69
Mates Sharon10b5-1
Chairman and CEO · Director
−$2.4M
Dec 04, 2024
27,667 sh · $85.62
Mates Sharon10b5-1
Chairman and CEO · Director
−$2M
Dec 04, 2024
23,333 sh · $86.00
Halstead Michael10b5-1
President
−$1.2M
Nov 13, 2024
13,371 sh · $88.17
Halstead Michael10b5-1
President
−$475.1K
Nov 13, 2024
5,343 sh · $88.92
Halstead Michael10b5-1
President
−$1.3M
Nov 12, 2024
15,105 sh · $88.72
Halstead Michael10b5-1
President
−$548.2K
Nov 12, 2024
6,116 sh · $89.63
Halstead Michael10b5-1
President
−$149.8K
Nov 12, 2024
1,648 sh · $90.89
Mates Sharon10b5-1
Chairman and CEO · Director
−$2.1M
Aug 30, 2024
28,203 sh · $72.73
Mates Sharon10b5-1
Chairman and CEO · Director
−$454.1K
Aug 30, 2024
6,193 sh · $73.32
Mates Sharon10b5-1
Chairman and CEO · Director
−$2.2M
Aug 29, 2024
29,832 sh · $72.44
Mates Sharon10b5-1
Chairman and CEO · Director
−$422.8K
Aug 29, 2024
5,772 sh · $73.25
Mates Sharon10b5-1
Chairman and CEO · Director
−$2.4M
Aug 28, 2024
32,459 sh · $72.74
Mates Sharon10b5-1
Chairman and CEO · Director
−$17.7K
Aug 28, 2024
240 sh · $73.70
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 05, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 50,163 | $84.06 | −$4.2M |
| Dec 05, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 1,534 | $84.69 | −$129.9K |
| Dec 04, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 27,667 | $85.62 | −$2.4M |
| Dec 04, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 23,333 | $86.00 | −$2M |
| Nov 13, 2024 | Halstead Michael10b5-1President | 13,371 | $88.17 | −$1.2M |
| Nov 13, 2024 | Halstead Michael10b5-1President | 5,343 | $88.92 | −$475.1K |
| Nov 12, 2024 | Halstead Michael10b5-1President | 15,105 | $88.72 | −$1.3M |
| Nov 12, 2024 | Halstead Michael10b5-1President | 6,116 | $89.63 | −$548.2K |
| Nov 12, 2024 | Halstead Michael10b5-1President | 1,648 | $90.89 | −$149.8K |
| Aug 30, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 28,203 | $72.73 | −$2.1M |
| Aug 30, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 6,193 | $73.32 | −$454.1K |
| Aug 29, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 29,832 | $72.44 | −$2.2M |
| Aug 29, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 5,772 | $73.25 | −$422.8K |
| Aug 28, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 32,459 | $72.74 | −$2.4M |
| Aug 28, 2024 | Mates Sharon10b5-1Chairman and CEO · Director | 240 | $73.70 | −$17.7K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Intra-Cellular Therapies, Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Bedminster, NJ
- Incorporated in
- DE
- SEC Central Index Key
- 0001567514
- Previously filed as
- Oneida Resources Corp.
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought ITCI
What the stock actually did in the 90 days following each open-market purchase
Don't check ITCI — let it ping you
Get told the moment an insider moves on ITCI
Pro watches Intra-Cellular Therapies, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add ITCI to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read ITCI insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have ITCI insiders bought or sold stock recently?
- No open-market purchases or sales by Intra-Cellular Therapies, Inc. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much ITCI stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 3 Intra-Cellular Therapies, Inc. insiders made no open-market purchases and 26 sales worth $35M. 25 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and no sales. The largest sale was Mates Sharon selling $4.2M on Dec 05, 2024.
- Where does ITCI insider trading data come from?
- From the Form 4 filings Intra-Cellular Therapies, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.